Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New PSMA scan aims to spot hidden prostate cancer spread

NCT ID NCT04745871

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 30 times

Summary

This study tested whether a special type of PET/CT scan, called PSMA PET/CT, can better detect if prostate cancer has spread to nearby lymph nodes before surgery. The scan uses a radioactive tracer that sticks to prostate cancer cells, making them visible. The goal was to help doctors plan more precise surgery for men with intermediate- or high-risk prostate cancer. However, the trial was stopped early, so we have less information than planned.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHRU de Brest

    Brest, 29609, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PSMA PET/CT scan (a type of imaging test using a radioactive tracer)

What this could lead to

If successful, this imaging test could help doctors more accurately decide the extent of surgery needed for prostate cancer, potentially reducing unnecessary procedures.

What could go wrong

The trial was terminated early, so results are limited. PSMA PET/CT is still being studied and may not be widely available or better than current standard imaging for all patients.

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.